Innovative Biopharmaceuticals Academic EventsThe inaugural ceremony of Suzhou Innovative Biomedical Research and Development Center was held at Dushu Lake on April 21. It is jointly established by State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences and SIP Bio & Nano Technology Development Co., Ltd. (the owner of BioBay), and participated by Soochow University and other parties. Professor Zhan Qimin, vice president of Chinese Academy of Medical Sciences, leader of the Expert Team of National 863 Program for High-tech Biology and Pharmaceuticals, and lead scientist of National 973 Key Basic Research Program, was appointed as the director general of Suzhou Innovative Biomedical Research and Development Center.
Professor Zhan, Zhu Kejiang, director of Jiangsu Department of Science and Technology, Ma Minglong, standing member of Suzhou CCP Standing Committee and secretary of Suzhou Industrial Park Management Committee CCP Committee, Zhu Xiulin, president of Soochow University and An Daochang, vice director of Biotechnology Development Center, Ministry of Science and Technology jointly launched Suzhou Innovative Biomedical Research and Development Center. Mr. Zhu Kejiang gave a speech at the Ceremony, saying, "The establishment of the Center is an effective development mode for exploring the R&D, results transformation, startups and public services of the biopharmaceutical industry."
The guests jointly launching Suzhou Innovative Biomedical Research and Development Center
Professor Zhan said, "The Center shall facilitate integration of the biopharmaceutical industry in BioBay with the state key science programs and the competent national authorities." He was graduated from the former Suzhou Medical College, and is now the vice president of Chinese Academy of Medical Sciences. He has the special feeling about Suzhou, and always keeps a close watch on the development of the biopharmaceutical industry in Suzhou Industrial Park. He received the engagement certificate from Mr. Ma Minglong, secretary of SIP CCP Committee in 2008, to act as the advisor of the biopharmaceutical industry in SIP, providing the authoritative and profession guidance on the development of the biopharmaceutical industry.
Professor Zhan Qimin, vice president of Chinese Academy of Medical Sciences and director general of Suzhou Innovative Biomedical Research and Development Center
Suzhou Innovative Biomedical Research and Development Center is located in the single house C5 in BioBay, and is a successful case of combination of the national core technologies and the resources of Suzhou, to establish the technical platform with the internationally competitive technical staff, technologies, operation mechanism and facilities, oriented at the significant requirements for health and medicine in China, and embracing the frontline technologies of the biopharmaceutical industry, the market and the international competition. The Center is staffed with 8 leading scientists, including, Professor Zhan Qimin, Ji Yun, vice director of National Engineering Research Center of Virus Biotechnology, Song Lei, deputy professor of Cardiology, Fuwai Cardiovascular Diseases Hospital, Peking Union Medical College, Lin Chen, vice director of Suzhou Innovative Biomedical Research and Development Center, Fan Saijun, professor of Soochow University and a Changjiang Scholar, Han Jian, director of US Hudson Alpha Biotechnology Institute, Li Fusheng, director of Gene Research, Primal Inc. (Seattle, USA), and Li Baomin, senior scientists of Gene Medicine Institute, South California University (USA). The Center shall establish the internationally leading molecular biology laboratory and the innovative drug research and development base.
Suzhou Innovative Biomedical Research and Development Center
The Center is located in the single house C5 in BioBay
With the operation of Suzhou Innovative Biomedical Research and Development Center, BioBay has established the public service platform integrating the basic analysis, professional analysis and the technical R&D platforms. Now the Basic Analysis Platform - Public Analysis Platform and Antibody Platform, which has been put into operation, has provided 18320 times of services as ended in March 2010, in which the services times increases by 382% in 2009 as compared with those last year; the services provided in March 2010 were 2378 times, increasing by 158% as compared with the same period last year. The Platform not only provides services to the companies in the Park, but also to Suzhou Key Laboratory of Environment and Biological Safety, No.1 Hospital of Soochow University, Shanghai No.6 People��s Hospital, Shanghai Jiaotong University and other institutions. The Public Services Platform established the cooperative laboratories with the international famous pharmaceutical companies, and provided totally 89 technical trainings for companies in BioBay, becoming an important carrier for HR services. Suzhou Innovative Biomedical Research and Development Center shall provide the national level technical and service supports directly to companies in the Park and companies in the entire Yangtze River Delta, to accelerate the regional industrial development and enhance the innovations. It shall become a technical output center and an accelerator of technical cooperation and technical results transformation in the Yangtze River Delta, providing the new opportunities and giving fresh impetus for the technical and industrial development and accelerating improvement of the independent innovation ability of Suzhou Industrial Park.